# Pentadeca Arginate (PDA): Evidence, Mechanism & Legal Status

> A clinical monograph on Pentadeca Arginate (PDA) — the L-arginine salt of BPC-157 marketed for tendon, gut and wound healing. Zero PDA-specific studies, borrowed preclinical data, and an unsettled 2026 legal status.

*Published 2026-06-30 · Updated 2026-07-01 · By Elena Soto, PharmD*

The short answer
Pentadeca Arginate (PDA) is **the arginine salt of BPC-157 — the same active molecule by another name**, not a new drug. A PubMed search for "pentadeca arginate" returns **zero results**: no human or preclinical study has ever tested PDA as a distinct entity, so its honest grade is **D** (at best C if the borrowed BPC-157 preclinical base is credited). It is not FDA-approved, sits in a 2026 regulatory gray zone, and is prohibited in sport at all times under WADA.[2](https://peptidevox.com/#r2)[7](https://peptidevox.com/#r7)

Pentadeca Arginate — marketed as PDA, pentadecapeptide arginate, BPC-157 arginate, or "BPC-157 stable" — is the L-arginine (di-arginine) salt of BPC-157, promoted for tendon, ligament and muscle repair, gut and mucosal healing, and wound recovery.[5](https://peptidevox.com/#r5) Its popularity in recovery circles has surged since 2024; its proof in humans is nonexistent. This monograph separates the rebrand from the reality.

*This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. PDA is not an FDA-approved drug; it is sold as a "research chemical not for human use" and is prohibited in sport. Dosing figures are reported strictly as seen in clinic and marketing materials for completeness — not as recommendations. Consult a licensed clinician before any health decision.*

## What is Pentadeca Arginate and how does it work?

"Penta-deca" means fifteen amino acids; "arginate" names the arginine counter-ion. PDA is therefore BPC-157 by another name — the same sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV), free-peptide molecular weight about 1419.55 Da, differing only in the salt paired with the peptide backbone.[4](https://peptidevox.com/#r4)[3](https://peptidevox.com/#r3) The arginate form was defined in a 2013 Diagen patent (WO2014142764A1, inventor Rudolf Ručman) as the "bepecin di-L-arginine salt" at a 1:2 molar ratio of peptide to L-arginine, pH-adjusted to 7.40.[3](https://peptidevox.com/#r3)

The mechanism story is entirely the parent peptide's, demonstrated only in animal and in-vitro models because the active molecule is identical. Reported signaling includes pro-angiogenic activation of VEGF receptor-2 (VEGFR2) and the early growth response gene EGR-1; modulation of the nitric-oxide system via eNOS-derived NO and cGMP/PKG; and induction of antioxidant proteins such as HO-1 and NQO-1.[4](https://peptidevox.com/#r4) A 2025 systematic review summarizes the musculoskeletal mechanism as enhanced growth-hormone-receptor expression plus angiogenesis with reduced inflammatory cytokines.[1](https://peptidevox.com/#r1) No single primary receptor target is confirmed, and none of this is established in humans. There are no published human pharmacokinetic data for PDA or BPC-157 in any salt form; the only PK work (rats and beagle dogs) reports an elimination half-life under about 30 minutes, with hepatic metabolism and renal and biliary excretion.[4](https://peptidevox.com/#r4)

## What is the one thing the arginine salt genuinely changes?

Exactly one PDA-specific claim has primary data behind it: chemical and storage stability. The Diagen patent provides HPLC measurements under several stressors, all showing the di-arginine salt dramatically outperforming the acetate.[3](https://peptidevox.com/#r3)

  Patent HPLC stability: BPC-157 acetate vs di-arginine salt (percent intact)

    Stress conditionBPC-157 acetateArg-BPC (di-arginine)

    Simulated gastric juice, pH 3.0, 37 °C, 5 h0.08%84.9%
    Aqueous solution, 50 °C, 388 h21.30%99.01%
    Boiling water, 100 °C, 1 h56.80%99.08%
    Solid state, 50 °C / 65% RH, 90 days85.90%99.07%

This is a real storage-stability and gastric-survival advantage rooted in chemistry: the arginine guanidinium group buffers toward neutral pH and suppresses acid-catalyzed degradation of the peptide's aspartate and glutamate residues.[3](https://peptidevox.com/#r3) But two caveats are decisive. First, popular vendor figures such as "1,000 times more stable" and oral bioavailability rising "from under 3 percent to over 90 percent" are marketing extrapolations from these chemistry numbers, not pharmacokinetic measurements, and appear in no peer-reviewed study.[5](https://peptidevox.com/#r5) Second, for the subcutaneous or intramuscular route most clinics actually use, the gastric-stability edge is largely irrelevant because the peptide bypasses the stomach. Once dissolved in tissue, the free BPC-157 peptide is delivered and its in-vivo pharmacology is expected to match the acetate.[5](https://peptidevox.com/#r5)

## What is the evidence by indication?

The central finding of this monograph is an absence: no PDA-specific studies exist. The 2025 PRISMA systematic review of the parent compound screened 544 articles from 1993 to 2024 and included 36 — of which 35 were preclinical and only one was human.[1](https://peptidevox.com/#r1) Not one studied PDA. Every indication below is therefore borrowed BPC-157 evidence, graded C at best and D as "PDA."

  Pentadeca Arginate evidence by indication (inherited from BPC-157)

    IndicationBest evidenceGrade

    Tendon / ligament / muscle / bone repairRodent functional, structural & biomechanical healing modelsC preclinical; D as PDA
    Gut / GI mucosal healing (ulcers, IBD)Animal ulcer, colitis & NSAID-lesion modelsC preclinical; D as PDA
    Wound healing / soft tissue & skinRodent angiogenesis & collagen-synthesis modelsC preclinical; D as PDA
    Knee / joint pain (human)One uncontrolled 12-patient retrospective case series (7/12 relief >6 mo)D (Level IV/V)

The orthopedic case is the most extrapolated. Rodent models report improved healing of tendon, ligament, muscle and bony injuries, plausibly via angiogenesis and fibroblast outgrowth.[1](https://peptidevox.com/#r1) The single human datapoint across the entire field is an uncontrolled, unblinded retrospective case series of 12 chronic-knee-pain patients given intra-articular BPC-157, in which 7 of 12 reported relief beyond six months — no control, no blinding, no validated outcomes, and not the arginate salt.[1](https://peptidevox.com/#r1) The gut indication is where the arginate's stability edge is invoked as a rationale for oral PDA, but that rationale is theoretical, not demonstrated in any human or PDA-specific study.[3](https://peptidevox.com/#r3) Readers can confirm the evidence gap directly via the negative PubMed query at [pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/?term=pentadeca+arginate).[2](https://peptidevox.com/#r2)

Proven vs hyped
Proven in humans: nothing. Genuinely documented: only the arginate's chemical/storage-stability edge over acetate — a patent property, not a clinical benefit. Hyped: tendon, gut and wound "healing," "1,000x stability," and ">90% oral bioavailability" — all preclinical, patent-extrapolated, or unverified vendor claims.[5](https://peptidevox.com/#r5)

## What doses appear in the literature?

Reported strictly as information, not a protocol — and clinics themselves concede no officially established human dosage exists for PDA.[6](https://peptidevox.com/#r6) The most common route is subcutaneous injection, often near the injury site, with intramuscular also used and oral capsule forms marketed on the arginate's acid stability.[6](https://peptidevox.com/#r6) Reported SC/IM figures are commonly cited around 200 to 250 µg per day starting, up to roughly 300 to 500 µg per day for more significant injury; some clinic protocols describe a loading phase of 500 µg to 1 mg per day for 7 to 10 days followed by 500 µg to 1 mg two to three times weekly — all mirroring conventional BPC-157 anecdotal dosing, with no validated titration or duration.[6](https://peptidevox.com/#r6) Lyophilized powder is reconstituted with bacteriostatic water per vendor instructions.[3](https://peptidevox.com/#r3) Because PDA is sold gray-market as "research use only," product identity, purity, dose accuracy and sterility are unverified.[8](https://peptidevox.com/#r8)

## How safe is Pentadeca Arginate?

No clinical safety dataset exists; the systematic review found no clinical safety data for BPC-157.[1](https://peptidevox.com/#r1) Anecdotal reports describe mild injection-site irritation, headache, nausea and dizziness, and the literature documents that the peptide has caused pain and possible necrosis when injected in aqueous or physiological-saline solution.[4](https://peptidevox.com/#r4) Animal toxicology is reassuring at studied doses — no deaths or abnormal findings at 20 mg/kg i.m. in rats or 10 mg/kg i.m. in dogs — but human exposure is far too sparse to detect anything beyond obvious reactions.[4](https://peptidevox.com/#r4) The dominant theoretical risk is mechanistic: PDA upregulates VEGFR2 and stimulates EGR-1, and because VEGF-family signaling is expressed in roughly half of studied human cancers, reviewers warn the peptide "may not be the right choice" where occult cancer cells could be present.[4](https://peptidevox.com/#r4) Pregnancy, breastfeeding and pediatric use are precautionary contraindications. In practice the largest real-world hazard is product quality from gray-market vendors — unverified identity, endotoxin and heavy-metal content.[8](https://peptidevox.com/#r8)

## What is the FDA and WADA status in 2026?

PDA is not an FDA-approved drug, has no USP/NF monograph, and is not a component of any approved drug, so it meets none of the three statutory criteria for legal 503A bulk compounding.[8](https://peptidevox.com/#r8) Critically, "pentadeca arginate" is not separately listed on any FDA bulks list — nominations address only BPC-157 free base and acetate — confirming PDA tracks BPC-157's fate rather than escaping it.[9](https://peptidevox.com/#r9) PDA emerged after the late-2023 Category 2 classification of BPC-157, with vendors arguing the arginine counter-ion made it a distinct entity, but under the FDA's "essentially a copy" doctrine a salt change with the same active sequence and route is not a legally distinct substance.[8](https://peptidevox.com/#r8)[10](https://peptidevox.com/#r10) On April 15, 2026 the FDA removed 12 peptides — including BPC-157 — from 503A Category 2, but only because the nominations were withdrawn, not because the substances were found safe; this leaves BPC-157 and PDA in an unauthorized transitional gray zone.[11](https://peptidevox.com/#r11) A Pharmacy Compounding Advisory Committee review is scheduled for July 23-24, 2026 (docket FDA-2025-N-6895), but PCAC votes are advisory only and the earliest plausible legal compounding access is late Q3 2026, with nothing guaranteed.[9](https://peptidevox.com/#r9)[12](https://peptidevox.com/#r12)

For athletes the picture is unambiguous. BPC-157 in any salt form, including PDA, is prohibited at all times under category S0 (non-approved substances) of the WADA Prohibited List — in and out of competition, with no Therapeutic Use Exemption, and the salt form does not alter the classification.[7](https://peptidevox.com/#r7) The U.S. Department of Defense also prohibits it for service members. "Research use only" labeling is not a shield: selling "not for human consumption" while supplying dosing and healing testimonials renders the research label legally void.[8](https://peptidevox.com/#r8)

**Bottom line.** Pentadeca Arginate is a marketing rebrand, not a new drug — the arginine salt of BPC-157, premised on a salt-form "distinctness" no regulator, monograph or court has accepted. The evidence gap is the verdict: zero PDA-specific studies of any kind, and a borrowed BPC-157 base that is 35-to-1 preclinical-to-human with no completed RCTs. Graded D as "Pentadeca Arginate," C only if generously crediting the parent preclinical base — legally unsettled and banned in sport. Regulatory facts here are current as of June 2026; the July 23-24, 2026 PCAC outcome was pending at the time of writing and should be re-verified after that date.

---
Source: https://peptidevox.com/peptide-encyclopedia/pentadeca-arginate-pda
Index: https://peptidevox.com/llms.txt · Full text: https://peptidevox.com/llms-full.txt